Verona Pharma plc - American Depositary Shares (VRNA) earnings
VRNA earnings moved a median of +0.87% by the close. Quarterly and annual VRNA reports and results, each read against the price at its own news timestamp. Back to the VRNA overview →
18 measured VRNA earnings events.
Where these VRNA earnings landedvs 18 measured VRNA earnings reactions
| Middle 50% of VRNA earnings reactions | -0.60% to +4.87% |
|---|---|
| Median reaction (to close) | +0.87% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 VRNA earnings events with a measured close landed between -0.60% and +4.87%; 72% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Verona Pharma plc For: Jun 30 | SEC filing · Form 10-Q | -0.04% | +0.07% | |
| Form 10-Q Verona Pharma plc For: Mar 31 | SEC filing · Form 10-Q | -5.10% | -1.30% | |
| Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | -5.10% | -1.30% | |
| Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update | Press release | +0.45% | +0.72% | |
| Form 10-K Verona Pharma plc For: Dec 31 | SEC filing · Form 10-K | +1.04% | +0.18% | |
| Form 10-Q Verona Pharma plc For: Sep 30 | SEC filing · Form 10-Q | -1.54% | +15.61% | |
| Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -1.54% | +15.61% | |
| Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update | Press release | -0.06% | +1.19% | |
| Form 10-Q Verona Pharma plc For: Jun 30 | SEC filing · Form 10-Q | +0.45% | +7.52% | |
| Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.45% | +7.52% | |
| Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update | Press release | +1.48% | +5.48% | |
| Form 10-Q Verona Pharma plc For: Mar 31 | SEC filing · Form 10-Q | +1.77% | +1.02% | |
| Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | -1.70% | -3.34% | |
| Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update | Press release | -1.12% | +1.19% | |
| Form 10-K Verona Pharma plc For: Dec 31 | SEC filing · Form 10-K | -4.01% | -5.38% | |
| Form 10-Q Verona Pharma plc For: Sep 30 | SEC filing · Form 10-Q | +0.65% | +0.33% | |
| Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | +0.83% | +3.03% | |
| Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update | Press release | +1.34% | -0.82% |
Keep exploring
More VRNA: analyst actions → · SEC filings → · VRNA overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Novartis AG (NVS) | 326 | +0.03% | 51% |
| Theravance Biopharma, Inc. - Ordinary Shares (TBPH) | 326 | +0.10% | 57% |
| Bionano Genomics, Inc. (BNGO) | 321 | -0.94% | 31% |
| Wave Life Sciences, Inc. (WVE) | 321 | -0.14% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.